SCHEMBL564652

SCHEMBL564652

Nc1cc(Cc2ccccc2)ccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.68
HNF4A P41235 1/20 0.58
GAA P10253 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 2/20 0.55
MAPT P10636 2/20 0.55
POLB P06746 1/20 0.55
RAB9A P51151 1/20 0.55
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.52
HSP90AA1 P07900 1/20 0.52
ALOX12 P18054 1/20 0.52
HTT P42858 1/20 0.52
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29350695 1.00 IDH1 (0.68) IDH1HNF4AGAAMEN1KMT2A
SCHEMBL29860720 0.89 GAA (0.67) IDH1GAAMEN1KMT2AKDM4E
SCHEMBL564615 0.89 GAA (0.67) IDH1GAAMEN1KMT2AKDM4E
SCHEMBL29412587 0.89 GAA (0.67) IDH1GAAMEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL21173959 0.87 GAA (0.64) IDH1GAAMEN1KMT2AKDM4E
SCHEMBL564946 0.86 KDM4E (0.53) IDH1HNF4AGAAMEN1KMT2A
SCHEMBL565060 0.86 ALDH1A1 (0.58) IDH1HNF4AGAAMEN1KMT2A
SCHEMBL564633 0.86 ESR1 (0.58) IDH1HNF4AGAAMEN1KMT2A
SCHEMBL565083 0.85 GAA (0.52) IDH1HNF4AGAAMEN1KMT2A
SCHEMBL564637 0.84 KDM4E (0.80) IDH1HNF4AGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0164120-B1 A METHOD FOR HIGH CONTRAST DEVELOPMENT OF A SILVER HALIDE PHOTOGRAPHIC MATERIAL FUJI PHOTO FILM CO., LTD. (JP) 1989-11-15 EP claimed
CN-112961891-B Method for preparing icariin by using biphasic enzymatic reaction 西安巨子生物基因技术股份有限公司 2024-01-26 CN disclosed
US-10898516-B2 Compositions and methods of treating diabetic retinopathy CASE WESTERN UNIVERSITY (US) 2021-01-26 US disclosed
US-10568851-B2 Compounds and methods of treating ocular disorders CASE WESTERN RESERVE UNIVERSITY (US) 2020-02-25 US disclosed
US-10426773-B2 Systems pharmacology for treating ocular disorders CASE WESTERN UNIVERSITY (US) 2019-10-01 US disclosed
EP-2509596-B1 GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS UNIV CASE WESTERN RESERVE (US) 2019-08-28 EP disclosed
US-20190255102-A1 COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY CASE WESTERN UNIVERSITY 2019-08-22 US disclosed
US-10272106-B2 Compositions and methods of treating diabetic retinopathy CASE WESTERN RESERVE UNIVERSITY (US) 2019-04-30 US disclosed
US-20190099420-A1 SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS CASE WESTERN UNIVERSITY 2019-04-04 US disclosed
US-10208049-B2 Compounds and methods of treating ocular disorders CASE WESTERN RESERVE UNIVERSITY (US) 2019-02-19 US disclosed
EP-0387725-A2 Production of thiophene-2,5-dicarboxylic acid diesters and tetrahydrothiophene-2,5-dicarboxylic acid diesters SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1990-09-19 EP disclosed
EP-0203521-B1 A PROCESS FOR PREPARING NEGATIVE IMAGES FUJI PHOTO FILM CO., LTD. (JP) 1989-12-13 EP disclosed
US-4824764-A HIGH CONTRAST IMAGES FUJI PHOTO FILM CO., LTD. (JP) 1989-04-25 US disclosed
US-4740452-A DIHYDROXYBENZENE-TYPE DEVELOPER, SULFITE PRESERVATIVE, AND AMINE DERIVATIVE FUJI PHOTO FILM CO., LTD. (JP) 1988-04-26 US disclosed
EP-0203521-A2 A process for preparing negative images FUJI PHOTO FILM CO., LTD. (JP) 1986-12-03 EP disclosed
EP-0123902-A2 Procedure for the determination of peroxidase activity by end dilution titration and means for its realization Byk-Sangtec Diagnostica GmbH & Co. KG (DE) 1984-11-07 EP disclosed
US-4334005-A Transition metal photoreduction systems and processes EASTMAN KODAK COMPANY (US) 1982-06-08 US disclosed
US-4314019-A NONSILVER PHOTOGRAPHY; COBALT AMMINE COMPLEXES) QUINONE REDUCING AGENTS EASTMAN KODAK COMPANY (US) 1982-02-02 US disclosed
US-4201588-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, CARBAZIDES OR QUINONES AS PHOTOREDUCTANT; EXTERNAL HYDROGEN SOURCE EASTMAN KODAK COMPANY (US) 1980-05-06 US disclosed
US-3985763-A DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10426773-B2 Systems pharmacology for treating ocular disorders GRK1, MTNR1A, MTNR1B IDH1 3431/4885HNF4A 1864/4885GAA 496/4885
US-20190255102-A1 COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY GPR119, ARRB1, GRK1 IDH1 3818/4885HNF4A 1722/4885GAA 1536/4885
US-10272106-B2 Compositions and methods of treating diabetic retinopathy GPR119, ARRB1, GRK1 IDH1 3818/4885HNF4A 1722/4885GAA 1536/4885
US-20190099420-A1 SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS GRK1, MTNR1A, MTNR1B IDH1 3431/4885HNF4A 1864/4885GAA 496/4885
US-10568851-B2 Compounds and methods of treating ocular disorders ALDH1A2, TXNRD2, TXNRD1 IDH1 1937/4885HNF4A 1605/4885GAA 204/4885
US-10208049-B2 Compounds and methods of treating ocular disorders ALDH1A2, NR2E3, LRAT IDH1 2069/4885HNF4A 1200/4885GAA 251/4885
US-10898516-B2 Compositions and methods of treating diabetic retinopathy GPR119, ARRB1, GRK1 IDH1 3818/4885HNF4A 1722/4885GAA 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.